Enterprise Value

120.8M

Cash

38.76M

Avg Qtr Burn

-11.39M

Short % of Float

7.20%

Insider Ownership

9.56%

Institutional Own.

46.38%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Avasopasem Manganese (GC4419) Details
Head and neck cancer, Cancer

NDA

Resubmission

Avasopasem Manganese (GC4419) Details
Lung cancer, Esophagitis, Non-small cell lung carcinoma

Phase 2a

Update

Avasopasem Manganese (GC4419) Details
Infectious disease, COVID-19

Failed

Discontinued

Rucosopasem Details
Cancer, Non-small cell lung carcinoma

Failed

Discontinued

Rucosopasem Details
Pancreatic cancer, Cancer

Failed

Discontinued